Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma

Atsuhiro Kumabe; Sadatomo Zenda; Atsushi Motegi; Masakatsu Onozawa; Naoki Nakamura; Takashi Kojima; Hiroyuki Daiko; Naoyuki Shigematsu; Tetsuo Akimoto

doi:10.21873/anticanres.11919

Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma

Atsuhiro Kumabe, Sadatomo Zenda, Atsushi Motegi, Masakatsu Onozawa, Naoki Nakamura, Takashi Kojima, Hiroyuki Daiko, Naoyuki Shigematsu, Tetsuo Akimoto

Department of Radiology (Radiation Oncology)

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Background/Aim: We assessed the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) in patients with squamous cell carcinoma of the cervical esophagus. Patients and Methods: We retrospectively analyzed 37 patients treated with definitive CCRT. The patients received radiotherapy at a fraction dose of 2 Gy (total; 60 or 70 Gy) and concurrent chemotherapy. Adjuvant chemotherapy consisted of 1 to 2 cycles of 5-fluorouracil plus cisplatin or nedaplatin. Results: The median follow-up was 119.0 months, the 10-year overall survival, progression-free survival and laryngectomy-free survival rates were 35.6, 19.9 and 30.2% respectively. In the univariate analysis, T stage (T4 vs. T1-3) was the only prognostic factor for PFS. The most common acute toxicity was leukocytopenia (Grade 3; 27%). As for late toxicities, 4 patients (11%) developed Grade 2 or 3 esophageal strictures. Conclusion: The results of this study demonstrated that CCRT yielded satisfactory clinical outcomes with acceptable toxicities.

Original language	English
Pages (from-to)	5039-5044
Number of pages	6
Journal	Anticancer research
Volume	37
Issue number	9
DOIs	https://doi.org/10.21873/anticanres.11919
Publication status	Published - 2017 Sept

Keywords

Cervical esophageal carcinoma
Chemoradiotherapy
Prognostic factor
Squamous cell carcinoma

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.11919

Cite this

@article{f930e1e819c84c56be8711a81cdb058e,

title = "Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma",

abstract = "Background/Aim: We assessed the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) in patients with squamous cell carcinoma of the cervical esophagus. Patients and Methods: We retrospectively analyzed 37 patients treated with definitive CCRT. The patients received radiotherapy at a fraction dose of 2 Gy (total; 60 or 70 Gy) and concurrent chemotherapy. Adjuvant chemotherapy consisted of 1 to 2 cycles of 5-fluorouracil plus cisplatin or nedaplatin. Results: The median follow-up was 119.0 months, the 10-year overall survival, progression-free survival and laryngectomy-free survival rates were 35.6, 19.9 and 30.2% respectively. In the univariate analysis, T stage (T4 vs. T1-3) was the only prognostic factor for PFS. The most common acute toxicity was leukocytopenia (Grade 3; 27%). As for late toxicities, 4 patients (11%) developed Grade 2 or 3 esophageal strictures. Conclusion: The results of this study demonstrated that CCRT yielded satisfactory clinical outcomes with acceptable toxicities.",

keywords = "Cervical esophageal carcinoma, Chemoradiotherapy, Prognostic factor, Squamous cell carcinoma",

author = "Atsuhiro Kumabe and Sadatomo Zenda and Atsushi Motegi and Masakatsu Onozawa and Naoki Nakamura and Takashi Kojima and Hiroyuki Daiko and Naoyuki Shigematsu and Tetsuo Akimoto",

note = "Funding Information: This study was supported, in part, by Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (JSPS KAKENHI grant numbers 15K19838 and 16K10412), Health Science Research grants from the Ministry of Health and Welfare, and the National Cancer Center Research and Development Fund (28-A-14).",

year = "2017",

month = sep,

doi = "10.21873/anticanres.11919",

language = "English",

volume = "37",

pages = "5039--5044",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "9",

}

TY - JOUR

T1 - Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma

AU - Kumabe, Atsuhiro

AU - Zenda, Sadatomo

AU - Motegi, Atsushi

AU - Onozawa, Masakatsu

AU - Nakamura, Naoki

AU - Kojima, Takashi

AU - Daiko, Hiroyuki

AU - Shigematsu, Naoyuki

AU - Akimoto, Tetsuo

N1 - Funding Information: This study was supported, in part, by Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (JSPS KAKENHI grant numbers 15K19838 and 16K10412), Health Science Research grants from the Ministry of Health and Welfare, and the National Cancer Center Research and Development Fund (28-A-14).

PY - 2017/9

Y1 - 2017/9

N2 - Background/Aim: We assessed the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) in patients with squamous cell carcinoma of the cervical esophagus. Patients and Methods: We retrospectively analyzed 37 patients treated with definitive CCRT. The patients received radiotherapy at a fraction dose of 2 Gy (total; 60 or 70 Gy) and concurrent chemotherapy. Adjuvant chemotherapy consisted of 1 to 2 cycles of 5-fluorouracil plus cisplatin or nedaplatin. Results: The median follow-up was 119.0 months, the 10-year overall survival, progression-free survival and laryngectomy-free survival rates were 35.6, 19.9 and 30.2% respectively. In the univariate analysis, T stage (T4 vs. T1-3) was the only prognostic factor for PFS. The most common acute toxicity was leukocytopenia (Grade 3; 27%). As for late toxicities, 4 patients (11%) developed Grade 2 or 3 esophageal strictures. Conclusion: The results of this study demonstrated that CCRT yielded satisfactory clinical outcomes with acceptable toxicities.

AB - Background/Aim: We assessed the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) in patients with squamous cell carcinoma of the cervical esophagus. Patients and Methods: We retrospectively analyzed 37 patients treated with definitive CCRT. The patients received radiotherapy at a fraction dose of 2 Gy (total; 60 or 70 Gy) and concurrent chemotherapy. Adjuvant chemotherapy consisted of 1 to 2 cycles of 5-fluorouracil plus cisplatin or nedaplatin. Results: The median follow-up was 119.0 months, the 10-year overall survival, progression-free survival and laryngectomy-free survival rates were 35.6, 19.9 and 30.2% respectively. In the univariate analysis, T stage (T4 vs. T1-3) was the only prognostic factor for PFS. The most common acute toxicity was leukocytopenia (Grade 3; 27%). As for late toxicities, 4 patients (11%) developed Grade 2 or 3 esophageal strictures. Conclusion: The results of this study demonstrated that CCRT yielded satisfactory clinical outcomes with acceptable toxicities.

KW - Cervical esophageal carcinoma

KW - Chemoradiotherapy

KW - Prognostic factor

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85029439113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029439113&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11919

DO - 10.21873/anticanres.11919

M3 - Article

C2 - 28870931

AN - SCOPUS:85029439113

SN - 0250-7005

VL - 37

SP - 5039

EP - 5044

JO - Anticancer research

JF - Anticancer research

IS - 9

ER -

Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this